drugset / Trial / NCT03950037
SANCC: Clinical Trial Early Intervention
Phase 2
Withdrawn
Oregon Health and Science University
National Institute of Neurological Disorders and Stroke (NINDS) · collabUniversidad Peruana Cayetano Heredia · collab
NaSingle-groupOpen-labelTreatment
Summary
Subarachnoid neurocysticercosis (SANCC) is a severe infection of the brain by the tapeworm Taenia solium. People who have this infection are usually diagnosed late in the disease process leading to very poor prognosis. This trial studies the safety of early medical intervention in people who have SANCC but do not have symptoms. The trial will enroll 18 participants in Peru.
Timeline
- Start
- 2022-01-01
- Primary completion
- 2023-04
- Completion
- 2023-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Albendazole | Small molecule | 15 mg/kg | — |